Royalty Pharma (RPRX) Balance Sheet: Assets & Liabilities

Royalty Pharma (RPRX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Royalty Pharma reported total assets of $19.62B and total liabilities of $9.91B. Shareholders' equity was $6.48B, down 37.4% from $10.34B a year earlier. Total debt stood at $8.97B against $637.50M in cash and short-term investments, a net debt position of $8.33B. That puts debt-to-equity at 1.38, compared with 0.74 a year earlier.

Royalty Pharma Balance Sheet Analysis

Values in billions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Royalty Pharma plc (RPRX) - Annual data in billions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	0.62	0.93	0.48	1.71	1.54	1.01	0.25	1.92	1.38
Short-Term Investments	0.02	0.06	0.76	0.72	0.65	1.64	0.55	0.46	0.00
Cash & Short-Term Investments	0.64	0.99	1.23	2.43	2.19	2.65	0.79	2.39	1.38
Accounts Receivable	0.88	0.03	0.02	0.04	0.07	0.04	0.04	0.20	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	-0.90	0.85	0.02	0.09	0.69	0.01	0.00	0.02	1.57
Total Current Assets	0.62	1.80	1.27	2.55	2.88	2.70	0.83	2.61	2.95
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Investments	0.17	1.26	15.10	14.23	0.91	13.28	11.48	8.67	0.00
Goodwill	0.92	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.00	0.01	0.00	0.00	0.01	0.03	0.05	0.08	0.00
Other Non-Current Assets	15.97	15.16	0.01	0.03	13.72	0.01	0.09	0.02	0.00
Total Non-Current Assets	17.06	16.42	15.11	14.26	14.64	13.32	11.62	8.76	8.43
Total Assets	19.62	18.22	16.38	16.81	17.52	16.02	12.45	11.37	11.37
Current Liabilities
Accounts Payable	0.02	0.01	0.02	0.01	0.01	0.01	0.01	0.00	0.00
Short-Term Debt	0.38	1.00	0.00	1.00	0.00	0.00	0.28	0.28	0.28
Current Portion of Long-Term Debt	0.38	1.00	-	1.00	-	-	-	-	-
Accrued Liabilities	0.11	0.10	0.05	0.05	0.06	-	-	-	-
Other Current Liabilities	0.24	0.24	0.15	0.16	0.17	0.30	0.04	0.29	0.10
Total Current Liabilities	0.64	1.25	0.16	1.17	0.17	0.31	0.33	0.58	0.38
Non-Current Liabilities
Long-Term Debt	8.59	6.61	6.14	6.12	7.10	5.82	5.96	6.24	6.52
Other Non-Current Liabilities	0.68	0.01	0.00	0.00	0.00	0.00	0.02	0.00	0.00
Total Non-Current Liabilities	9.27	6.63	6.14	6.12	7.10	5.82	5.98	6.24	6.52
Total Liabilities	9.91	7.88	6.30	7.29	7.27	6.12	6.31	6.82	6.90
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	3.28	3.28	0.00
Retained Earnings	2.36	2.85	2.52	1.96	2.26	1.92	2.83	1.22	0.00
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.03	0.00	-0.01	0.00
Treasury Stock	0.00	0.00	0.00	0.00	-	-	-	-	-
Additional Paid-in Capital	4.12	4.10	4.01	3.66	3.50	2.86	0.00	0.00	4.46
Minority Interest	3.24	3.40	3.56	3.90	4.47	5.08	0.04	0.06	0.00
Shares Outstanding	0.43	0.45	0.45	0.44	-	-	-	-	-
Total Stockholders' Equity	6.48	10.34	6.53	5.63	10.25	4.82	6.11	4.49	4.46
Total Liabilities & Equity	19.62	18.22	16.38	16.81	17.52	16.02	12.45	11.37	11.37

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Royalty Pharma Balance Sheet

How much debt does Royalty Pharma have?

Royalty Pharma had total debt of $8.97B as of Dec 31, 2025, against $637.50M in cash and short-term investments. Its debt-to-equity ratio was 1.38. Total debt was $7.61B a year earlier.

What are Royalty Pharma's total assets?

Royalty Pharma reported total assets of $19.62B as of Dec 31, 2025, up 7.7% from $18.22B a year earlier. Total liabilities were $9.91B.

What is Royalty Pharma's shareholders' equity?

Royalty Pharma's shareholders' equity was $6.48B as of Dec 31, 2025, or about $15.11 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition